RA

DCP vs. MRP | Choosing the Right Regulatory Pathway in the EU

DCP vs. MRP | Choosing the Right Regulatory Pathway in the EU

Navigating the European regulatory landscape can be complex, especially when seeking approval for medicinal products across multiple countries. Two key procedures streamline this process: Decentralized Procedure (DCP) and Mutual Recognition Procedure (MRP). While both facilitate multi-country approvals, understanding their differences is essential for strategic regulatory planning. Decentralized Procedure (DCP) DCP ... Read More
Handling Conflicting Regulatory Requirements | A Strategic Approach

Handling Conflicting Regulatory Requirements | A Strategic Approach

In global regulatory affairs, one of the most complex challenges we face is resolving conflicting requirements from different regulatory bodies. Each agency has its own set of expectations, shaped by regional regulations, scientific perspectives, and risk tolerance. Navigating these differences requires a strategic, risk-based approach to ensure compliance while maintaining ... Read More
Key Challenges in Bioequivalence (BE) Studies

Key Challenges in Bioequivalence (BE) Studies

Bioequivalence (BE) studies are the foundation of generic drug approvals, ensuring that alternative formulations provide the same therapeutic effect as the reference product. However, regulatory expectations and methodologies are evolving rapidly to address complex formulations and emerging technologies. Key Challenges in BE Studies Complex Generics & Locally Acting Drugs Highly ... Read More
Navigating Bioequivalence Study Guidelines Across Global Regulatory Bodies

Navigating Bioequivalence Study Guidelines Across Global Regulatory Bodies

When conducting bioequivalence (BE) or bioavailability (BA) studies for regulatory approval, guidelines from different regulatory bodies must be adhered to. Here’s a summary of the key considerations and variations across major regulatory agencies Regulatory Guidelines Comparison USFDA Special Cases: Study Design: EMA Acceptance Range: Study Design: WHO Study Design: MHRA ... Read More
Differences Between eCTD and ACTD Dossier

Differences Between eCTD and ACTD Dossier

eCTD (Electronic Common Technical Document) ACTD (ASEAN Common Technical Dossier) Key Differences Read also: Resource Person: KABYA PRATAP ROYAL
Site Master File in Pharmaceutical Industry

Site Master File in Pharmaceutical Industry

In the world of pharmaceutical manufacturing, understanding and maintaining high standards of quality is not just important, it’s imperative. A key element in this quality assurance landscape is the Site Master File (SMF), but what is it? An SMF is a comprehensive document that provides detailed information about the production ... Read More
ASEAN Common Technical Document (ACTD)

ASEAN Common Technical Document (ACTD)

It is a submission format for dossiers used in most ASEAN countries (Association of South-East Asian Nations). The main aim of ACTD is to regulate the pharmaceutical regulations of the ASEAN member countries to complement and facilitate the objective of AFTA (ASEAN Free Trade Area), particularly, the elimination of technical ... Read More
Stability Data and Evaluation of Finished Pharmaceutical Products

Stability Data and Evaluation of Finished Pharmaceutical Products

Stability Studies: A Brief Introduction Stability studies are crucial for determining the shelf life and storage conditions of pharmaceutical products, ensuring their efficacy and safety throughout their lifespan. Long-term and accelerated studies are conducted to evaluate how products respond to various environmental conditions. Data from these studies help establish expiration ... Read More
Regulatory Guidelines for CSV

Regulatory Guidelines for CSV

Embarking on the path to a successful Computer System Validation (CSV) roadmap begins with a solid understanding of the applicable regulatory requirements within your industry and region. Investing the time to understand which regulations you must comply with, which are advantageous, and which, are the gold standard, is a crucial ... Read More
Patents and Exclusivity in Pharmaceutical Industry

Patents and Exclusivity in Pharmaceutical Industry

Did you know that “patent” and “exclusivity” are two of the most commonly searched terms on the FDA website? Generics account for more than 80% of prescription drugs in the US, and that number continues to grow. With approaching patent expirations of several top selling prescription brand-name drugs, sponsors of ... Read More
Drug Master File (DMF) in Pharmaceutical Industry

Drug Master File (DMF) in Pharmaceutical Industry

Drug Master File (DMF) is a package of confidential, proprietary assets, specifying the formula, processes, materials, test methods, and other information relevant to the manufacture of product used in the composition, packaging, and/or processing of pharmaceuticals and/or biologics. Types of DMFs Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel ... Read More